|
GlobeNewswire Not for distribution by US newswire or in United States VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that at the Company's Annual and Special General Meeting, held on December 30, 2020 in Toronto, all resolutions were duly passed by shareholders. The Company also announces that since November 26, 2020, the date of the filing of our condensed consolidated interim financial statements for the nine months ended September 30, 2020, we have received aggregate proceeds of $115,000 from the exercise of previously issued (January 2018) warrants, having an exercise price of $0.10 per warrant. As of December 30, 2020, the Company has $1.3 million in cash and cash equivalents. "This has been a very exciting year for us and as we begin 2021, we wish to thank our shareholders for their continued support. The funds from the exercise of warrants, together with our last private placement will enable us to continue to progress our research programs," said David Goren, Vaxil's Chairman and Chief Executive Officer. HAPPY NEW YEARS |